Russian University completes human trials of a coronavirus vaccine

Henrietta Strickland
July 13, 2020

Though there is little information about when the vaccine's commercial production will start, Lukashev said the developers are pondering over a plan, considering all factors. Bharat Biotech is developing the vaccine in collaboration with the Indian Council of Medical Research (ICMR).

"If things go to plan, CSL will rapidly advance production of tens of millions of doses and move the program into later stage clinical testing, regulatory approval, large-scale manufacture and distribution", Project director Professor Trent Munro said.

According to local media, the trial will see people injected with two doses of the vaccine every four weeks.

Given their needs of a different level of protection, Russian Federation has not started developing a special vaccine for children.

The Russian COVID-19 vaccine is reported to use a weakened virus to deliver small parts of a pathogen and stimulate an immune response. 14 potential candidates for the COVID19 vaccine are at the Phase I stage.

Precision Vaccinations published coronavirus vaccine development news.

The report, citing Citing Alexander Lukashev, the director of the Institute of Medical Parasitology, Tropical, and Vector-Borne Diseases at Sechenov University, said the study has been conducted to check the COVID-19 vaccine's safety when given to humans and it has been successfully completed.

These candidates, however, remain just that - candidates. One is developed by the University of Oxford and AstraZeneca is at Phase III.

"The research has been completed and it proved that the vaccine is safe". Wuhan Institute and Sinopharm's COVID19 vaccine candidate is at the Phase II stage.

Failures make vaccine development even more expensive. "The vaccine arrived when the crisis was already over", Dr Kiat said. "It corresponds to the safety of those vaccines that are now on the market", Lukashev told Sputnik.

The US accounted for the world's highest number of infections at over 33 lakh. India is third worst affected with over 8.7 lakh people reported to have COVID-19. For comparison, there are now only 82 vaccine candidates still in active development for tuberculosis, according to the WHO. Meanwhile, many experts believe that a COVID-19 vaccine will be ready only by mid-2021. Even for ebola, the most recent vaccine approved for use by the World Health Organization, phase I trials began in November 2014, and the drug got World Health Organization approval for use in November 2019, a full five years later.

Rukmini S.is a Chennai-based journalist.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER